Context Therapeutics (CNTX) Change in Accured Expenses (2020 - 2026)

Context Therapeutics has reported Change in Accured Expenses for 7 years, with the latest figure at -$1.5 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 265.58% year-over-year to -$1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (up 1288.76% YoY) and the FY2025 annual result came in at $4.2 million, up 775.44% from the prior year.
• Change in Accured Expenses slipped to -$1.5 million in Q1 2026 per CNTX's latest filing, from $2.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $2.2 million in Q4 2025 and troughed at -$1.5 million in Q1 2026.
• A 5-year average of $179233.8 and a median of $206373.0 in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses slumped 454.29% in 2024, then surged 21306.42% in 2025.
• Over 5 years, Change in Accured Expenses stood at -$222150.0 in 2022, then tumbled by 335.41% to -$967261.0 in 2023, then soared by 98.94% to -$10276.0 in 2024, then soared by 21306.42% to $2.2 million in 2025, then tumbled by 167.3% to -$1.5 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$1.5 million, $2.2 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.